Interactive Features

Quiz

Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT

04/02/2024

Oncology

Quiz

R/R Pre-B ALL Treatment With Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin With or Without Blinatumomab

08/01/2023

True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.

True or False: A treatment...

08/01/2023

Oncology

Quiz

Quiz: Use of Inotuzumab Ozogamicin Induction Therapy for De Novo Acute B-Lymphoblastic Leukemia

03/01/2023

True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.

True or False: 3 cycles of...

03/01/2023

Oncology

Quiz

Use of Blinatumomab During Consolidation for High-Risk Ph-Negative B-Cell Precursor ALL

03/01/2023

True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.

True or False: The use of...

03/01/2023

Oncology

Quiz

Quiz: ASCT From Matched Sibling Donors vs Matched Unrelated Donors in Adult High-Risk ALL

10/05/2022

True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.

True or False: Allogeneic...

10/05/2022

Oncology

Quiz

Quiz: Complete Remission Rate Among Patients With R/R B-Cell ALL With Anti-CD19 CAR T-Cell Therapy

08/23/2022

True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.

True or false: The complete...

08/23/2022

Oncology

Quiz

Quiz: Patients With ALL Are More Likely to Receive Salvage Chemotherapy After Treatment With Which Prior Therapy?

08/05/2022

True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...

True or False: Findings from the...

08/05/2022

Oncology

Quiz

Quiz: Is This CAR-T Therapy a Potential Treatment Option for R/R B-ALL?

03/07/2022

True or false: According to the phase 2 ZUMA-3 trial, brexucabtagene autoleucel may offer a treatment option for patients with R/R B-ALL.

True or false: According to the...

03/07/2022

Oncology

Test Your Knowledge

Quiz: How Does Tisagenlecleucel Affect Activity in ALL?

03/07/2022

True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.

True or false: Tisagenlecleucel...

03/07/2022

Oncology

Test Your Knowledge

Quiz: How Does Tisagenlecleucel Affect Activity in ALL?

03/07/2022

True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.

True or false: Tisagenlecleucel...

03/07/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology